3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Postoperative Complications
1
Neoplasms
1
Frailty
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Immunonutrition Diet
×
Gastrointestinal
×
Clear all
NCT01023412
2025-12-10
IPOD-3
Société des Produits Nestlé (SPN)
Phase NA
Terminated
107 enrolled